Sector: Healthcare · Industry: 生技醫療業 · Exchange: TPEx
BioGend Therapeutics Co., Ltd. engages in the research and development, and sale of orthopedic medical devices and related products. The company offers RevoCart, an autologous cartilage repair system; and SoufCut, an autologous adipose tissue collection system. It develops BiG-001, an osteoinductive bone graft substitute; BiG-006 for lumbar interbody fusion; and BiG-009, an autologous cartilage repair system for articaular cartilage. The company operates in Taiwan, Hongkong, Chinese Mainland, and Malaysia. BioGend Therapeutics Co., Ltd. was founded in 2016 and is based in Taipei, Taiwan.
Headquarters: Taipei, TW · Website: https://www.biogend.com
博晟生醫 (6733) is a publicly traded company in the Healthcare sector (生技醫療業), listed on TPEx. Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.
Search companies · Macro trends · Industries · Product categories · Baskets